 |
Advertisement
|
BROWSE topics
Intravenous Dilution Guidelines
Phenylephrine (Neosynephrine ®) |
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. |
Usual Diluents |
| D5W, NS |
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
|
Standard Dilution: [40 mg] [250 ml] [Titrate] Range: [10 to 40 mg] [250 ml] [Titrate] Some support for the following: [50 mg] [250 ml] [Titrate] [80 mg] [250 ml] [Titrate] [100 mg] [250 ml] [Titrate] Alternative (min dilution): [40 mg] [100 ml] [Titrate] Central line required. Peripheral line may be used for short periods (Max concentration: 10mg/250 ml) while preparation for central line is underway. |
Stability / Miscellaneous |
|
EXP: 2 DAYS (RT). Label: Do not Refrigerate. (Alpha agonist). May be given IM,SC, IV push, or by continuous infusion. Treat mild/moderate hypotension, also PSVT. IV infusion: usual initial rate: 0.1 to 0.18 mg/min (100 to 180mcg/min) (titrate). Usual maintenance rate: 40-60 mcg/min. Maximum rate (range): infusion rates as high as 8 to10 mcg/kg/min may be required in shock [Usual maximum dosing range reported: 0.4 to 9.1 mcg/kg/minute ]. IV bolus therapy: usual dose: 0.5 mg [range: 0.1 to 1 mg (max)] repeat q10-15 min as needed. PSVT: 0.5 mg rapid IV push, subsequent doses may be increased in increments of 0.1 to 0.2mg. Calculation of drip rate (40 mg/250) (ml/hr) = (mg/min) x 375. |
Disclaimer |
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. |
